The oncomir microRNA-125b (miR-125b) is up-regulated in a variety of human neoplastic blood disorders and constitutive up-regulation of miR-125b in mice can promote myeloid and B cell leukemia. We found that miR-125b promotes myeloid and B cell neoplasm by inducing tumorigenesis in hematopoietic progenitor cells. Our study demonstrates that miR125b induces myeloid leukemia by enhancing myeloid progenitor output from stem cells as well as inducing immortality, self-renewal, and tumorigenesis in myeloid progenitors. Through functional and genetic analyses, we demonstrated that miR-125b induces myeloid and B cell leukemia by inhibiting IRF4 but through distinct mechanisms; it induces myeloid leukemia through repressing IRF4 at the mRNA level without altering the genomic DNA and induces B cell leukemia via genetic deletion of the gene encoding IRF4.
Introduction
MicroRNAs have been found to be dysregulated in several types of human and mouse cancers, including carcinomas and leukemias. As happens with protein-coding oncogenes, noncoding oncomirs can provoke cancers by dysregulating developmental, signaling and cell survival pathways in different cell types. For the majority of oncomirs, it is not clear how a single microRNA can induce cancer development in various cell types. Potentially, an oncomir can suppress the same target(s) in different cell types to promote tumorigenesis, or it can inhibit distinct cell-specific targets to induce cancer development.
The oncomir microRNA-125b (miR-125b) is up-regulated in a myriad of neoplastic blood disorders, including acute myeloid leukemia (AML) and B-cell precursor acute lymphoblastic leukemia (BCP-ALL) [1] [2] [3] . Importantly, we and other researchers showed that enforced constitutive over-expression of miR-125b in mice induces myeloid, B cell, and T cell leukemia [4] [5] [6] [7] , indicating that miR-125b can provoke the oncogenic state in a range of hematopoietic cells. Interestingly, we found that miR-125b over-expression initially impairs the development of B cells whereas others found that it induces B cell leukemia [5, 6] . This suggests that miR-125b might initially repress the development of B cells but that these cells might acquire secondary mutational or epigenetic events that transform them into cancer cells. To date, the mechanism by which miR-125b induces tumorigenesis in different hematopoietic lineages is unknown.
Previously, we found that down-regulating the expression of the direct miR-125b target IRF4 was sufficient to recapitulate the activated phenotype observed upon over-expressing miR-125b in bone marrow-derived macrophages [8] . Relevant to leukemia, the expression of Irf4 is down-regulated in a range of hematopoietic cancer cell lines [9] as well as in human patients with AML, chronic myeloid leukemia (CML), and acute lymphoblastic leukemia (ALL) [10, 11] . Also, deletion of IRF4 in mice exacerbates the development of myeloid leukemia and For personal use only. on July 14, 2014. by guest bloodjournal.hematologylibrary.org From leads to development of B cell leukemia [12] [13] [14] . However, whether repression of IRF4 plays a functional role in miR-125b-induced myeloid and B cell leukemia remains to be tested.
In this study, we have investigated the cellular and molecular mechanisms by which miR-125b induces the development of myeloid and B cell leukemia. We found that miR-125b induces cancer development by initiating tumorigenesis in myeloid and B precursor cells. Our data also indicates that in both cases miR-125b induces myeloid and B cell leukemia by inhibiting IRF4 expression. Whereas miR-125b induces tumorigenesis in myeloid cells by repressing the expression of IRF4 at the mRNA and protein level, it promotes oncogenesis in B cells by provoking genetic deletion of IRF4. Thus, miR-125b represents a novel paradigm by which an oncomir induces cancer development in multiple cell lineages by modulating the same signaling pathway but via distinct mechanisms.
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Methods

DNA Constructs
pMG, pMSCV-IRES-GFP (MIG), pMG-miR-125b, and pMiR-report IRF4 3'UTR vectors have been described [5, 8] . pMIG-miR-125b co-expresses GFP and miR-125b. pMIG-IRF4 coexpresses GFP and IRF4. pHcRed-miR125b and pmCherry-miR125b co-express miR-125b and HcRed or mCherry, respectively (Supp. Table 1 for cloning primers).
Infection of BMCs, bone marrow reconstitution, and in vitro cell proliferation assays
To generate MG and MG-125b mice, lethally irradiated C57bl/6 recipient mice were injected with virally transduced bone marrow cells (BMCs). Briefly, donor C57bl/6 BMCs were transduced with miR-125b over-expressing vector (pMG-miR-125b or pMIG-miR-125b) through two to four rounds of spin infection, which achieved 25-and 186-fold higher miR-125b overexpression (Supp. Fig. S7 ). The expression levels are within range of the level of miR-125b over-expression observed in human patients with leukemia or myelodysplastic syndromes, which range from several to 262-fold above normal [1, 6, 15] . For the in vitro proliferation assays, BMCs and sorted Lin -cKit + Sca1 -MPs were cultured and passaged in 50ng/mL SCF, and sorted Lin -cKit + Sca1 + HSPCs were cultured in media containing 50ng/mL SCF, 50ng/mL IL6, and 25ng/mL IL3. All animal studies were approved by the IACUC. 
Transplantation of miR-125b-induced cancer cells and fluorescent activated cell sorting
Sca1
-cells (Lin = ILR7a, Thy1, Cd11b, Cd11c, B220, Ter119, CD3e, NK1.1, GR-1) were sorted from MG-125b mice when they were moribund. Cells were sorted using the FACSAria (BD Biosciences) or iCyte (Sony Biotech) instrument. Flow cytometric antibodies were purchased from eBioscience or Biolegend.
Single cell analysis and cell differentiation assay
MiR-125b over-expressing Lin -cKit + Sca1 -MPs were passaged six times in 50ng/mL SCF media. Single cells were plated. One month later, an aliquot of the expanded cells were assayed for granulocytes formation and some cells were cultured in 20ng/mL MCSF or J558L-GMCSF conditioned media to differentiate into macrophages and dendritic cells, respectively.
In vitro proliferation assay with rescued expression of IRF4
For in vitro proliferation assays, BMCs were first infected with pHcRed-miR-125b retroviruses that express miR-125b and HcRed. Subsequently, cells were infected with pMIG or pMIG-IRF4
retroviruses. HcRed + GFP + cells were sorted and cultured in 50ng/mL SCF.
Competitive repopulation of miR-125b over-expressing cells with rescued IRF4
expression.
Donor BMCs were infected with mCherry + miR-125b over-expressing virus (pmCherry-miR125b vector). The cells were then infected with GFP + virus (pMIG vector) or GFP + IRF4 overexpressing virus (pMIG-IRF4 vector) and transplanted into irradiated C57bl/6 mice.
Transplantation of sorted miR-125b over-expressing cells with restored IRF4 expression
BMCs were infected with GFP + miR-125b over-expressing retroviruses or co-infected with HcRed + miR-125b over-expressing (pHcRed-miR-125b vector) and GFP + IRF4 over-expressing retroviruses (pMIG-IRF4 vector). GFP + cells or GFP + HcRed + cells were sorted from the former and latter group of cells, respectively. The sorted BMCs were transplanted into irradiated C57bl/6 mice.
Exome sequencing and comparative genomic hybridization microarray (aCGH)
See supplemental methods for detailed experimental setup and data analysis. The microarray GEO accession number is: GSE58900.
Results
MiR-125b over-expressing leukemic cells are serially transplantable
To examine the ability of miR-125b-induced myeloid cancer cells to serially propagate, we over-expressed miR-125b through bone-marrow reconstitution experiments using the MSCV-GFP + (MG)-based retroviral system in mice (hereon denoted as 'MG-125b') [5] . When the MG-125b mice developed frank myeloid leukemia, cells from the spleen or bone marrow were transferred into sub-lethally irradiated secondary recipients. These recipients were moribund or died within 70 days ( Fig. 1A ) and developed leukemia indicated by increased white blood cell count ( Fig. S1A) and splenomegaly ( Fig. S1B) . Recipient mice that received cells from control 'MG' mice did not develop cancer and remained healthy through the duration of the study (Fig. 1A) . Remarkably, transplantation of miR-125b-induced cancer cells from secondary recipients into tertiary non-irradiated immuno-competent recipients also induced myeloid leukemia in the mice (Fig. 1A, Fig. S1C-D) . Collectively, our data indicates that the myeloid cancer induced by miR-125b over-expression is serially transplantable.
Genetic analyses of miR-125b myeloid cancer
Using deep-sequencing technologies, it has been determined that cancer cells can acquire few to thousands of secondary mutations in their exomes [16] [17] [18] [19] [20] . Thus, we sorted GFP + Cd11b + myeloid cancer cells induced by miR-125b over-expression and subjected them to exome deep-sequencing analysis. The first sample (sample #1) was harvested from a mouse two months after bone marrow reconstitution, which we validated as cancerous cells as demonstrated by the ability of these cells to be transplanted into a non-irradiated recipient mouse (data not shown). The second sample (sample #2) was harvested from a miR-125b
For personal use only. on July 14, 2014. by guest bloodjournal.hematologylibrary.org From over-expressing mouse three months after reconstitution; this mouse developed frank myeloid leukemia as characterized by moribund feature, exacerbated myeloid cell count in the blood (27x higher than normal), and splenomegaly (data not shown). The third sample (sample #3) was harvested from miR-125b-induced myeloid leukemic cells that were serially transplanted into recipient mice to ensure that we were analyzing cancerous cells in our deep-sequencing analysis. The deep-sequencing data sets were filtered based on a 0.1% false discovery rate, and cancer-specific mutations were obtained by subtracting those that were also identified in normal healthy mice. From the three independent experiments, we identified two, four, and thirty-two mutations from samples #1, #2, and #3, respectively (Fig. 1B , Supp. Table 2 ). The variations in the number of mutations from the different samples might be due to the different time at which they were harvest after bone marrow reconstitution. We have not ruled out the possibility that a small fraction of the myeloid cancer cells might have random mutations, which is outside of the deep-sequencing detection limit. However, our data suggests that the majority of miR-125b-driven myeloid cancer cell populations in the samples tested have relatively few nucleotide mutations in the coding regions and do not have widespread genomic instability. (Fig. 1C) at a similar time scale and rate (100%) compared to those transplanted with miR-125b over-expressing WT BMCs (Fig. 1D) , indicating that the development of myeloid leukemia provoked by miR-125b does not require miR-125b over-expressing lymphocytes.
Over-expression of miR-125b in primary BMCs
Next, we tested whether over-expressing miR-125b in BMCs in vitro could induce cellular hyper-proliferation and recapitulate the myeloproliferative phenotype observed in mice.
We over-expressed miR-125b in BMCs and cultured them in cytokine-supplemented media (SCF+IL3+IL6, SCF+IL-3 or SCF+IL-6) that supports growth and differentiation of HSCs, myeloid progenitors, and mature myeloid cells. Indeed, over-expression of miR-125b in vitro elevated the growth rate of BMCs ( Fig. S2A-C) and induced hyper-expansion of myeloid cells ( Fig. 2A) . MiR-125b over-expressing BMCs cultured in SCF alone, which supports growth of hematopoietic stem and progenitor cells, also grew faster (Fig. 2B) , suggesting that miR-125b induces hyper-proliferation in part due to its effect in stem/progenitor cells. Indeed, growth of BMCs with ectopic miR-125b expression generated higher number of Lin -cKit + Sca1 -cells (Fig.   2C ). In normal counterparts, Lin -cKit + Sca1 -cells represent myeloid progenitors/MPs.
Consistently with elevated number of myeloid progenitors, miR-125b over-expressing BMCs generated more dendritic cells when subjected to a methylcellulose-based colony-forming assay (Fig. S2D) or differentiated into dendritic cells in liquid culture (Fig. 2D) . MiR-125b overexpressing cells also formed more colonies in methylcellulose assay when cultured in present of SCF+IL3+IL6 ( Fig. S2E) although the cells did not serially re-plate (data not shown). Thus, our in vitro assay recapitulated the phenotype observed with over-expressing miR-125b in mice with higher numbers of myeloid progenitors and differentiated Cd11b + myeloid cells [5] .
Moreover, we investigated whether miR-125b over-expression is also sufficient to transform and immortalize BMCs in vitro. Indeed, whereas control cells died after several
For personal use only. on July 14, 2014. by guest bloodjournal.hematologylibrary.org From passages, miR-125b over-expressing cells continued to grow indefinitely (Fig. 2E) . When we injected miR-125b over-expressing BMCs that had been cultured in vitro into sublethally irradiated recipient mice, the cells dominated the blood of these mice and produced myeloid leukemia (Fig. 2F ) marked by splenomegaly (Fig. 2G) and bone marrow pallor (Fig 2H) . These data suggest that the cultured miR-125b over-expressing BMCs were transformed in vitro into cancer cells capable of inducing malignancy in vivo.
Effect of over-expressing miR-125b in hematopoietic stem and progenitor cells
Next, we tested whether miR-125b over-expression elevates the myeloid progenitor pool by enhancing the hematopoietic output of cells upstream of MPs, such as hematopoietic stem and progenitor cells (HSPCs). We cultured sorted MG and miR-125b Lin -cKit + Sca1 + (LKS + ) cells ( Fig. S3A ) and found that those with miR-125b-over-expression generated higher number of cells overall ( Fig. 3A) with a moderate increase in absolute LKS + cell numbers (Fig. 3B ) after six days of growth. When we instead looked at the Lin -cKit + Sca1 -(LKS -) population, the cellular output was dramatically higher in the miR-125b over-expressing samples ( Fig. 3C ) with exaggerated ratio of LKS -to LKS + cells (Fig. 3D) . Overall, our data suggests that miR-125b functions in HSPCs and increases the output of downstream MPs. Next, we tested whether miR-125b also functions intrinsically in MPs to accelerate the proliferation of these cells. We cultured LKS -cells sorted from BMCs transduced with MG or miR-125b encoding retroviruses.
We found that the cells with ectopic miR-125b expression grew much faster ( Fig. 3E ) and generated more myeloid cells (Cd11b + ) of both granulocytic (GR1 + ) and non-granulocytic lineages (Cd11b + GR1 -) (Fig. 3F) . In addition, the miR-125b-overexpressing cells were also more resistant to cell death as indicated by propidium iodide staining (Fig. S3B) . Thus, miR125b induces hyper-proliferation and resistance to cell death of MPs in vitro. S3C ). Collectively, this data indicates that miR-125b over-expression induces self-renewal of
MPs in vitro.
To test whether miR-125b over-expression induces tumorigenesis in myeloid progenitors, we transplanted sorted MPs from MG-125b mice into sublethally irradiated C57bl/6 recipients. Indeed, the recipient mice were moribund within 70 days and developed frank myeloid leukemia characterized by large excess of myeloid and myeloblast cells in the peripheral blood ( Fig. 3H) , splenomegaly ( Fig. 3I ) and bone marrow pallor ( Fig. 3J) , and dissemination of cancer cells into non-lymphoid tissues (liver, lung, kidney) (data not shown). In further support that miR-125b induces myeloid leukemia through progenitor cells, injection of terminally differentiated miR-125b over-expressing dendritic cells into mice did not induce leukemia ( Fig. S3D-F) , indicating the requirement of progenitor state for miR-125b to initiate tumorigenesis.
IRF4 expression rescues miR-125b-induced myeloid leukemia
Next, we investigated signaling pathways regulated by miR-125b to induce cancer development. Previously, we and other labs showed that miR-125b directly inhibits the expression of the transcription factor IRF4 [8, 24, 25] . We first confirmed that miR-125b inhibits
For personal use only. on July 14, 2014. by guest bloodjournal.hematologylibrary.org From IRF4 expression in primary mouse sorted LKS + and LKS -cells ( Fig. S4A-B ) and represses a luciferase reporter linked to the 3'UTR of IRF4 (Fig. S4C ). Next, we tested and found that reintroduction of IRF4 without its 3'UTR ( Fig. S4D-E ) into miR-125b-over-expressing BMCs was sufficient to reverse the hyper-proliferative phenotype induced by miR-125b ( Fig. 4A ) and prevented miR-125b-mediated myeloid expansion in vitro (Fig. S4F ).
Moreover, we tested the effect of uncontrolled IRF4 expression on miR-125b-overexpressing mice. To this end, we retrovirally transduced BMCs with a mCherry + miR-125b-overexpressing vector and then co-infected these cells with retroviruses expressing both GFP and IRF4 (lacking its UTR) or with GFP controls (Fig. 4B ). These unsorted retrovirally transduced
BMCs were then transplanted into C57Bl/6 recipient animals. After reconstitution, we found that mice transplanted with cells co-infected with IRF4-GFP and miR125b-mCherry vectors were deficient of cells expressing both miR-125b and IRF4 (mCherry + GFP + population) (Fig. 4C, Fig.   S4G ). They did, however, have a prominent population of mCherry + GFP -cells (Fig. 4C) ,
demonstrating that the cells that persisted in these mice were those expressing only miR-125b
but not ones co-expressing IRF4. In contrast, recipient mice transplanted with cells transduced with 125b-mCherry and GFP control vector contained prominent amounts of mCherry + GFP + cells ( Fig. 4C, Fig. S4G ). Collectively, our data indicates that hematopoietic cells that overexpress miR-125b alone robustly outcompete those with uncontrolled expression of IRF4, suggesting that IRF4 inhibits the enhanced proliferative capacity induced by miR-125b in vivo.
Finally, we examined whether rescued expression of IRF4 could inhibit myeloid leukemia provoked by miR-125b over-expression in mice. To this end, we transplanted into recipient mice GFP + BMCs that over-express miR-125b alone or along with restored IRF4 expression. Both populations of BMCs engrafted in the recipients as demonstrated by GFP positivity in the blood of these mice. Whereas the recipient mice transplanted with the former group of cells exhibited For personal use only. on July 14, 2014. by guest bloodjournal.hematologylibrary.org From severe myeloid hyperplasia after three months, the animals that received cells with restored IRF4 expression had normal myeloid counts (Fig. 4D) . As expected, the mice transplanted with miR-125b over-expressing cells had exaggerated development of myeloid in their spleens ( Fig.   4E ) accompanied by bone marrow pallor (Fig. 4F) , which are pathognomonic features of miR125b-mediated myeloid leukemia, while those with restored IRF4 expression had normal splenic myeloipoiesis and displayed normal reddish bone marrow ( Fig. 4E-F) . Collectively, our data indicates that suppression of IRF4 is important for miR-125b to induce myeloid leukemia and restoration of IRF4 can inhibit disease development.
MiR-125b over-expression induces B cell cancer harboring IRF4 deletion
We confirmed our previous finding that MG-125b mice have impaired B cell development ( Fig. 5A) [5]. Curiously, others have shown that B cell-restricted over-expression of miR-125b induces lymphoblastic leukemia in mice [6] . We posited that our experimental mice might be dying from complications associated with myeloid leukemia before manifesting features of B cell leukemia. To examine whether miR-125b promotes B cell leukemia in our experimental setting, we sorted the few GFP + CD19 + B cells from MG-125b mice when they developed myeloid leukemia and transplanted these B cells into C57bl/6 recipients. The cells were able to engraft in the secondary recipients ( Fig. 5B ) and proved lethal within two months, generating a fulminant CD19 + cancer (Fig. 5C) . Moreover, the resultant GFP + CD19 + cancer cells were serially transplantable into sublethally irradiated or non-irradiated recipient mice for up to 11 generations ( Fig. S5A ), inducing B cell leukemia ( Fig. 5D ) and in some cases B cell lymphoma ( Fig. 5E ) in the recipients. The development of B cell leukemia in these mice was also marked by splenomegaly (Fig. 5F ) and dissemination of GFP + CD19 + into non-hematopoietic organs, including the lung, liver, and kidney (Fig. S5B) Nevertheless, our experiment indicates that B cell maturation is not required for miR-125b to induce lymphomagenesis.
In our experiments, miR-125b ectopic over-expression initially repressed B cell genesis ( Fig. 5A ) but some cells of this lineage became cancerous later ( Fig. 5B-F) , leading to the possibility that induction of B cell leukemia may result from the accumulation of secondary genetic mutations involved in cellular transformation. To test this possibility, we performed comparative genomic hybridization microarray experiments (aCGH) of miR-125b B cancer cells to identify genomic alterations that might have occurred. In two independent experiments, we found that the B cancer cells induced by over-expression of miR-125b had an extra copy of chromosome 11 (Fig. 6A, Fig. S6A ). This characteristic was specific to miR-125b-induced B cancer cells and was not found in the myeloid cancer cells (Fig. S6A) . G-band karyotyping
For personal use only. on July 14, 2014. by guest bloodjournal.hematologylibrary.org From analysis confirmed that the miR-125b-induced B cancer cells indeed harbor trisomy 11 (Fig.   6B ). No obvious inversions or translocations were identified through karyotyping. Further, the aCGH experiments indicated that the IgK (chromosome 6) and IgH (chromosome 12) loci had suffered deletions in the cancerous B cells harvested from two separate groups of mice (Fig.   6A, Fig. S6B ), suggesting that these loci had been undergo VDJ rearrangement. Thus, we performed flow cytometric analyses to characterize these cancer B cells further and found that they were CD43 + CD24 + IgM -cKit -(data not shown) with one group of cells being IgK + IgG1 + (group #1) and another being predominantly IgK -IgG1 - (Fig. 6C) , indicating the former group of cells have productively rearranged their immunoglobulin loci whereas the latter did so nonproductively.
Strikingly, in both of our independent aCGH experiments, we found that cancer B cells induced by miR-125b over-expression harbored genetic deficiency at the tumor suppressor IRF4 locus (Fig. 6A, Fig. S6A ). The IRF4 genetic deletion was specific to the miR-125b-induced B cancer cells and was not observed in miR-125b-induced myeloid cancer cells (data not shown). Quantitative PCR analysis confirmed that the translational start site of both copies of IRF4 was deleted in the B cell cancer samples ( Fig. 6D-E) , and genotyping analyses revealed that almost the entire IRF4 coding region (exon2-exon7, amino acids 1-366 of 450 amino acids full length protein) was deleted ( Fig. 6D-F, Fig. S6C) . Interestingly, the population of cancer B cells was found to be heterogeneous with some expressing CD47 whereas others did not (Fig.   S6D) ; also, individual cancer B cell samples exhibited different IRF4 genetic breaks (Fig. S6E) 
Discussion
We set out to determine the mechanisms by which miR-125b induces development of leukemia. Relating to myeloid leukemia, we found that: (1) Myeloid cancer cells induced by miR125b exhibit relatively few mutational alterations; (2) miR-125b is able to promote tumorigenesis in vitro in a cell intrinsic manner; (3) Indeed, transplanting miR-125b over-expressing MPs could induce leukemia in recipient mice.
These data along with the fact that miR-125b over-expressing MPs could grow indefinitely and It has also been shown that human patients with B cell leukemia have elevated expression of miR-125b [1, 2, 31]. There are also reports of patients that acquire genetic mutations at the IRF4 locus [32] [33] [34] [35] . The increased expression of miR-125b could be caused by a chromosomal translocation that joins the miR-125b locus to, for instance, the immunoglobulin heavy chain gene regulatory elements [1, 6, 31] or it could be epigenetic. Because of our
For personal use only. on July 14, 2014. by guest bloodjournal.hematologylibrary.org From finding that over-expression of miR-125b associates with genetic aberration at the IRF4 gene, we speculate that miR-125b up-regulation in human cancer patients might result in a selection of IRF4 genetic mutations and consequently induce lymphoblastic leukemia. In support of this idea, it has already been established that IRF4 deletion in mice leads to the development of B cell leukemia, and over-expression of IRF4 inhibits the development of B cell leukemia in mice using cancer models induced by c-Myc and BCR/ABL [26, 28] . Of note, our finding that the IRF4 tumor suppressor gene is deleted in miR-125b-induced B cancer cells suggests that persistent up-regulation of miR-125b might no longer be required for maintaining oncogenicity of these cancer cells. Although additional experiments will be required to test this point, we speculate that inhibiting miR-125b will not be a suitable therapy for treating B cell leukemia invoked by this microRNA because permanent genetic lesions have occurred.
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